Since overexpression of the MEF2D‐ITGB1/4 axis correlates with inferior outcomes in multiple cancer types including HCC, this therapeutic strategy might be broadly utilized to inhibit cancer metastasis. This evidence concerns the gene MEF2D and cancer.